Maria E. Rodriguez-Aguirre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria E. Rodriguez-Aguirre has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Aaron N. Snead
Vividion Therapeutics, San Diego, USA
2 shared publicationsAli Tabatabaei
Vividion Therapeutics, San Diego, USA
2 shared publicationsBetty Lam
Vividion Therapeutics, San Diego, USA
2 shared publicationsChristie L. Eissler
Vividion Therapeutics, San Diego, USA
2 shared publicationsChristopher Claiborne
Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland
2 shared publicationsChu-Chiao Wu
Vividion Therapeutics, San Diego, USA
2 shared publications
Latest Publications
- Open Access
- 3 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8021) , E12
Author Correction: Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
- 3 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8021) , E12
Open AccessAuthor Correction: Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
- Top Cited Papers
- 24 April 2024
- Published by Springer Nature in Nature
- Vol. 629 (8011) , 435-442
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
WRN helicase is a promising target for treatment of cancers with microsatellite instability (MSI) due to its essential role in resolving deleterious non-canonical DNA structures that accumulate in cells with faulty mismatch repair mechanisms1,2,3,4,5. Currently there are no approved drugs directly targeting human DNA or RNA helicases, in part owing to the challenging nature of developing potent and selective compounds to this class of proteins. Here we describe the chemoproteomics-enabled discovery of a clinical-stage, covalent allosteric inhibitor of WRN, VVD-133214. This compound selectively engages a cysteine (C727) located in a region of the helicase domain subject to interdomain movement during DNA unwinding. VVD-133214 binds WRN protein cooperatively with nucleotide and stabilizes compact conformations lacking the dynamic flexibility necessary for proper helicase function, resulting in widespread double-stranded DNA breaks, nuclear swelling and cell death in MSI-high (MSI-H), but not in microsatellite-stable, cells. The compound was well tolerated in mice and led to robust tumour regression in multiple MSI-H colorectal cancer cell lines and patient-derived xenograft models. Our work shows an allosteric approach for inhibition of WRN function that circumvents competition from an endogenous ATP cofactor in cancer cells, and designates VVD-133214 as a promising drug candidate for patients with MSI-H cancers.
- 24 April 2024
- Published by Springer Nature in Nature
- Vol. 629 (8011) , 435-442
Top Cited PapersChemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
WRN helicase is a promising target for treatment of cancers with microsatellite instability (MSI) due to its essential role in resolving deleterious non-canonical DNA structures that accumulate in cells with faulty mismatch repair mechanisms1,2,3,4,5. Currently there are no approved drugs directly targeting human DNA or RNA helicases, in part owing to the challenging nature of developing potent and selective compounds to this class of proteins. Here we describe the chemoproteomics-enabled discovery of a clinical-stage, covalent allosteric inhibitor of WRN, VVD-133214. This compound selectively engages a cysteine (C727) located in a region of the helicase domain subject to interdomain movement during DNA unwinding. VVD-133214 binds WRN protein cooperatively with nucleotide and stabilizes compact conformations lacking the dynamic flexibility necessary for proper helicase function, resulting in widespread double-stranded DNA breaks, nuclear swelling and cell death in MSI-high (MSI-H), but not in microsatellite-stable, cells. The compound was well tolerated in mice and led to robust tumour regression in multiple MSI-H colorectal cancer cell lines and patient-derived xenograft models. Our work shows an allosteric approach for inhibition of WRN function that circumvents competition from an endogenous ATP cofactor in cancer cells, and designates VVD-133214 as a promising drug candidate for patients with MSI-H cancers.
- Open Access
- 19 March 2019
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (23) , 2252-2269
PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models
PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models
- 19 March 2019
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (23) , 2252-2269
Open AccessPD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models
PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models